Fundraising continued to drop in October, no drugmaker raised more than $30 million
Minhua Chu · 11/14/2022
September’s downward fundraising trend continued into October, with only 13 deals raising a total of $157 million.
READ MORE
Financing for China drugmakers hits the lowest of the year
Minhua Chu · 10/17/2022
Financing for Chinese drugmakers hit a 2022 low with 15 of 19 companies disclosing a total of only $346 million in funding.
READ MORE
Chinese pharma companies raised over half a billon USD in August
Minhua Chu · 09/15/2022
38 biotech companies secured financing this August, 31 of which disclosed figures totaling $563 million.
READ MORE
Four publicly traded drugmakers saw huge investments in July
Minhua Chu · 08/25/2022
Gene therapy, nucleic acid drugs and radiopharmaceuticals are attracting more investor attention.
READ MORE
Biotech fundraising in China warms up a little in June
Elise Mak · 07/25/2022
After a ‘biotech winter’, it seems the first signs of spring has arrived for the industry. Biotech fundraising trends showed more positive signs in June, with funds raised by Chinese players rising 42% from a month ago to reach $554 million.
READ MORE
China’s May fundraising indicates interest in early-stage biotech
Shi Yingzi · 06/20/2022
Chinese investors showed more support for young startups in May 2022 as four of them raised over RMB100 million each in early financing rounds, while late-stage drugmakers found fundraising more challenging than ever. Financing activity in May was also the weakest this year, with the least deals and lowest amount.
READ MORE
Pediatric drug development a new investment area in China
Shi Yingzi · 05/19/2022
A drugmaker specializing in medicines for children raising nearly $15.7 million in April 2022 shows a shifting interest toward this area. Early-stage biotech companies also made up 18 of the 27 financing deals.
READ MORE
RNA therapies making a comeback in March as China battles Omicron
Shi Yingzi · 04/18/2022
As China battles its worst COVID outbreak, investors have turned their attentions to RNA-based therapies again. But this time, companies are flogging their platform technologies rather than specific programs.
READ MORE
Chinese investors’ interest in cell and gene therapy remains strong
Shi Yingzi · 03/15/2022
Cell therapy and gene therapy companies extended a trend from the second half of 2021 by making up 11 of the 21 financing deals in February. PharmaDJ expects this trend to continue throughout the year.
READ MORE
READ MORE
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement